GLP-1 receptor agonists have revolutionized obesity treatment, producing significant weight loss and metabolic improvements. However, emerging evidence indicates that a substantial proportion of this loss may come from lean tissue, including muscle mass, an outcome with potential implications for long-term health. This presentation will explore the impact of GLP-1RA-induced weight loss on body composition and nutritional status, including the associated risk of malnutrition and its potential clinical consequences. Strategies to mitigate these effects through targeted nutrition and resistance training will also be discussed.
Dr. Carla Prado is a Distinguished University Professor and a Canada Research Chair in Integrative Nutrition, Body Composition, and Energy Metabolism (Tier 1). She is also a registered dietitian. She directs the Human Nutrition Research Unit, recognized as one of the world’s leading research and training facilities for body composition and energy metabolism assessments. Dr. Prado's research focuses on assessing nutritional status through precise measurements of body composition and energy metabolism. Her current research program investigates the prevalence and health outcomes of abnormal body composition phenotypes in patients with diverse chronic conditions. She is also developing targeted nutrition interventions to optimize body composition and improve health outcomes. Dr. Prado is an Associate Editor for two of the top journals in her field and serves on several international clinical guideline committees. She is a Fellow of the Canadian Academy of Health Sciences and a member of the Royal Society of Canada’s College of New Scholars, Artists, and Scientists. She has also been recognized as a Highly Cited Researcher by Clarivate™ (Web of Science).